Quick Answer
Entrada Therapeutics, Inc. reported Total Revenue of $25.42 million for fiscal year 2025.
Entrada Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $25.42M -87.9% |
$210.78M +63.4% |
$129.01M | — | — | — |
| Revenue (ASC 606) | $25.42M -87.9% |
$210.78M +63.4% |
$129.01M | — | — | — |
| Net Income | -$143.75M -319.0% |
$65.63M +1081.7% |
-$6.68M +92.9% |
-$94.62M -84.9% |
-$51.16M -92.9% |
-$26.52M |
| Diluted EPS | -$3.47 -306.5% |
$1.68 +940.0% |
-$0.20 +93.4% |
-$3.02 +63.0% |
-$8.16 +66.0% |
-$24.00 |
| Total Assets | $377.38M -28.3% |
$526.32M +12.2% |
$469.19M +86.1% |
$252.06M -17.6% |
$305.83M +602.6% |
$43.53M |
| Cash and Equivalents | $90.39M -10.7% |
$101.21M +49.7% |
$67.60M +49.7% |
$45.16M -84.5% |
$291.06M +645.5% |
$39.05M |
| Stockholders Equity | $306.13M -28.6% |
$428.68M +76.9% |
$242.36M +14.0% |
$212.55M -28.8% |
$298.72M +820.0% |
-$41.49M -167.4% |
| R&D Expense | $142.27M +13.5% |
$125.31M +25.5% |
$99.88M +50.0% |
$66.61M +85.4% |
$35.93M +70.2% |
$21.10M |
| Operating Income | -$157.90M -435.9% |
$47.01M +1586.7% |
-$3.16M +96.7% |
-$97.25M -90.2% |
-$51.13M -91.7% |
-$26.67M |
| Shares Outstanding | 38.28M +1.9% |
37.57M +12.4% |
33.44M +6.5% |
31.39M +0.5% |
31.22M +2409.7% |
1.24M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.61M | -91.8% | -17.2% |
| Revenue (ASC 606) | September 30, 2025 | $1.61M | -91.8% | -17.2% |
| Net Income | September 30, 2025 | -$44.13M | -214.5% | -2.4% |
| Diluted EPS | September 30, 2025 | -$1.06 | -202.9% | -1.9% |
| Total Assets | September 30, 2025 | $412.90M | -25.5% | -8.0% |
| Cash and Equivalents | September 30, 2025 | $93.29M | +19.5% | +28.7% |
| Stockholders Equity | September 30, 2025 | $340.72M | -19.3% | -10.2% |
| R&D Expense | September 30, 2025 | $38.36M | +22.7% | +1.3% |
| Operating Income | September 30, 2025 | -$47.05M | -117.2% | -0.4% |
| Shares Outstanding | September 30, 2025 | 38.22M | +2.2% | +0.5% |
- Entrada Therapeutics, Inc. reported Total Revenue of $25.42 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -87.9% in Total Revenue compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Revenue (ASC 606) of $25.42 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -87.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Net Income of -$143.75 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -319.0% in Net Income compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -306.5% in Diluted EPS compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Total Assets of $377.38 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -28.3% in Total Assets compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Cash and Equivalents of $90.39 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -10.7% in Cash and Equivalents compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Stockholders Equity of $306.13 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -28.6% in Stockholders Equity compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported R&D Expense of $142.27 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed an increase of +13.5% in R&D Expense compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Operating Income of -$157.90 million for fiscal year 2025.
- Entrada Therapeutics, Inc. showed a decrease of -435.9% in Operating Income compared to the prior fiscal year.
- Entrada Therapeutics, Inc. reported Shares Outstanding of 38.28 million shares for fiscal year 2025.
- Entrada Therapeutics, Inc. showed an increase of +1.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: